MBTPS1 and diabetes mellitus: Our paper, utilizing a diabetic model, explores fingolimod’s potential to mitigate diabetes-induced CNS damage, suggesting that its S1P-mediated effects could be valuable in reducing neurodegenerative processes linked to diabetic neuropathology.